Highly purified cannabidiol for epilepsy treatment: A systematic review of epileptic conditions beyond Dravet Syndrome and Lennox-Gastaut Syndrome

3/22/21–This systematic review aimed to summarize the currently available body of knowledge about the use of this US Food and Drug Administration/European Medicines Agency-approved oral formulation of pharmaceutical-grade CBD in patients with epileptic conditions. The currently available data suggest that response to treatment with a highly purified, plant-derived CBD oil-based solution can be seen in patients across a broad range of epilepsy disorders and etiologies. The existing evidence can provide preliminary support for additional research. Read